Biopharmaceutical Company Announces Notice of Allowance For Patent Over UC Treatment

Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company dedicated to developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, has recently announced a milestone in its intellectual property portfolio. The Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for patent application number 3,174,137, titled "Gut Microbiota Bioactivated PDE4 Inhibitor Precursors." This patent pertains to the composition of PALI-2108, the Company's lead product candidate, which is an orally administered, locally acting colon-specific Phosphodiesterase-4 (PDE4) inhibitor prodrug. PALI-2108 is being developed for the treatment of Ulcerative Colitis (UC), a chronic inflammatory bowel disease. $Palisade Bio(PALI.US)$